Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors

被引：4

作者：

Manson, Guillaume ^{[1
]}

Lemchukwu, Amaeshi Chukwunonye ^{[2
]}

Mokrane, Fatima-Zohra ^{[3
]}

Lopci, Egesta ^{[4
]}

Aide, Nicolas ^{[5
]}

Vercellino, Laetitia ^{[6
]}

Houot, Roch ^{[1
]}

Dercle, Laurent ^{[7
]}

机构：

[1] Univ Hosp Rennes, Dept Hematol, INSERM U1236, 2 Rue Henri le Guilloux, F-35000 Rennes, France

[2] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Internal Med, Bronx, NY 10467 USA

[3] Univ Hosp Toulouse, Dept Radiol, Toulouse, France

[4] IRCCS Humanitas Res Hosp, Nucl Med, Via Manzoni 56, Rozzano, MI, Italy

[5] Caen Univ Hosp, Nucl Med Dept, Caen, France

[6] Hop St Louis, AP HP, Dept Nucl Med, Paris, France

[7] Columbia Univ Med Ctr, Dept Radiol, New York, NY USA

来源：

EUROPEAN RADIOLOGY | 2022年 / 32卷 / 09期

关键词：

Hodgkin lymphoma; Immunotherapy; Immune checkpoint inhibitors; PET; Pseudoprogression indeterminate response; RESPONSE CRITERIA; ADVERSE EVENTS; NIVOLUMAB; EFFICACY; THERAPY; DISEASE; PD-1; ERA;

D O I：

10.1007/s00330-022-08669-8

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The development of immunotherapy has revolutionized cancer treatment, improving the outcome and survival of many patients. Immune checkpoint inhibitors (ICIs), the most common form of immunotherapy, use antibodies to restore T-cells' anti-tumor activity. Immune checkpoint inhibitors are gaining ground in the therapeutic strategy across various cancers. Although widely used in solid tumors, ICIs have shown remarkable efficacy in patients with Hodgkin lymphoma. 2-[F-18]Fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET)/CT is the gold standard to stage and monitor responses in Hodgkin lymphoma. This article reviewed the use of 2-[F-18]FDG-PET/CT in patients with Hodgkin lymphoma treated with ICI, focusing on image interpretation for response monitoring and detecting adverse events.

引用

页码：6536 / 6544

页数：9

共 57 条

[1] FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature [J].

Aide, Nicolas ;

Hicks, Rodney J. ;

Le Tourneau, Christophe ;

Lheureux, Stephanie ;

Fanti, Stefano ;

Lopci, Egesta .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) :238-250

[2] Immunotherapy in Hodgkin Lymphoma: The Road Ahead [J].

Ansell, Stephen M. .

TRENDS IN IMMUNOLOGY, 2019, 40 (05) :380-386

[3] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[4] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience [J].

Bekoz, H. ;

Karadurmus, N. ;

Paydas, S. ;

Turker, A. ;

Toptas, T. ;

Tuglular, T. Firatli ;

Sonmez, M. ;

Gulbas, Z. ;

Tekgunduz, E. ;

Kaya, A. H. ;

Ozbalak, M. ;

Tastemir, N. ;

Kaynar, L. ;

Yildirim, R. ;

Karadogan, I. ;

Arat, M. ;

Tanrikulu, F. Pepedil ;

Ozkocaman, V. ;

Abali, H. ;

Turgut, M. ;

Yuksel, M. Kurt ;

Ozcan, M. ;

Dogu, M. H. ;

Hacioglu, S. Kabukcu ;

Barista, I. ;

Demirkaya, M. ;

Koseoglu, F. D. ;

Toprak, S. K. ;

Yilmaz, M. ;

Demirkurek, H. C. ;

Demirkol, O. ;

Ferhanoglu, B. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2496-2502

[5] Measuring hope during the COVID-19 outbreak in the Philippines: development and validation of the state locus-of-Hope scale short form in Filipino [J].

Bernardo, Allan B. I. ;

Mendoza, Norman B. .

CURRENT PSYCHOLOGY, 2021, 40 (11) :5698-5707

[6] Classical Hodgkin lymphoma [J].

Brice, Pauline ;

de Kerviler, Eric ;

Friedberg, Jonathan W. .

LANCET, 2021, 398 (10310) :1518-1527

[7] 18F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors [J].

Castello, Angelo ;

Grizzi, Fabio ;

Qehajaj, Dorina ;

Rahal, Daoud ;

Lutman, Fabio ;

Lopci, Egesta .

LEUKEMIA & LYMPHOMA, 2019, 60 (02) :367-375

[8] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[9] Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab [J].

Chen, Aiping ;

Mokrane, Fatima-Zohra ;

Schwartz, Lawrence H. ;

Morschhauser, Franck ;

Stamatoullas, Apasia ;

de Colella, Jean-Marc Schiano ;

Vercellino, Laetitia ;

Casasnovas, Olivier ;

Chauchet, Adrien ;

Delmer, Alain ;

Nicolas-Virelizier, Emmanuelle ;

Ghesquieres, Herve ;

Moles-Moreau, Marie-Pierre ;

Schmitt, Anna ;

Dulery, Remy ;

Bouabdallah, Krimo ;

Borel, Cecile ;

Touati, Mohamed ;

Deau-Fischer, Benedicte ;

Peyrade, Frederic ;

Seban, Romain-David ;

Manson, Guillaume ;

Armand, Philippe ;

Houot, Roch ;

Dercle, Laurent .

JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (05) :649-654

[10] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Lee, Hun Ju ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Lin, Jianxin ;

Kim, Eunhee ;

Nahar, Akash ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

BLOOD, 2019, 134 (14) :1144-1153

← 1 2 3 4 5 6 →